PartnershipJun 23, 2026, 02:02 PM
Coherus Oncology, Zumutor Partner for Phase 1 ZM008/LOQTORZI Trial
AI Summary
Coherus Oncology, Inc. and Zumutor Biologics Inc. announced a clinical collaboration and supply agreement to conduct a Phase 1 trial. The study will evaluate ZM008, Zumutor's novel NK checkpoint antibody, in combination with Coherus' PD-1 inhibitor LOQTORZI (toripalimab-tpzi). This trial, identified as NCT06451497, aims to enroll up to 45 patients with various solid tumors, including colorectal, head and neck, non-small cell lung cancer, and urothelial cancers. Coherus will provide LOQTORZI, while Zumutor will sponsor the trial, with both companies retaining commercial rights to their respective compounds.
Key Highlights
- Coherus Oncology and Zumutor Biologics formed a clinical collaboration and supply agreement.
- Agreement for a Phase 1 trial of ZM008 (Zumutor) combined with LOQTORZI (Coherus).
- Trial (NCT06451497) to evaluate combination in solid tumors like colorectal, head and neck, NSCLC.
- Study will enroll up to 45 patients across dose-escalation and expansion cohorts in the U.S.
- Coherus will supply LOQTORZI; Zumutor will sponsor the Phase 1 clinical trial.
- Both companies retain all commercial rights to their respective compounds.
Price Impact
More from CHRS